trial

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

NCTId NCT00977522
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 207 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2010-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
207 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-11
Primary completion
2010-09
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-03463275

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

37 total
Cerritos, United StatesChula Vista, United StatesEscondido, United StatesGarden Grove, United StatesGlendale, United StatesLong Beach, United StatesLong Beach, United StatesNational City, United StatesParamount, United StatesTorrance, United StatesWashington D.C., United StatesWashington D.C., United States

Linked catalysts

1
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative — primary completion2010-09

Facts & assertions

4 sourced
Enrollment
207
Phase
PHASE2
Primary Completion Date
2010-09
Status
TERMINATED
relationships
The graph out of here
drug
PF-03463275
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication